Antagonist of adenosine A2A receptor
Ciforadenant is one of our main projects and is an oral small molecule antagonist of the adenosine A2A receptor. By precisely targeting and blocking A2A receptors on immune cells, ciforadenant may unleash their cancer-killing properties.
Ciforadenant is designed to block adenosine in the tumor microenvironment to bind to A2A receptors, so that the tumor lose the function of avoiding the attack by the immune system. Results from several pre-clinical models and human clinical trials have demonstrated that ciforadenant was active alone in patients with some cancers. Pre-clinical research results have been published in some famous journals and Clinical data have been presented at several conferences, including American Society of Clinical Oncology, American Cancer Research Association and Cancer Immunotherapy Association.
Anti-CD73Inhibitor of Adenosine production, anti-CD73 antibody
CPI-006 is a humanized anti-73 monoclonal antibody. Unlike most antibodies, CPI-006 is a designed smart antibody and has other distinct properties: to enhance the activity and trafficking capacity of immune cells, to further reduce the destructive capabilities of cancer cells.
CPI-006 binds to CD73 and appears to inhibit production of immunosuppressive adenosine of tumor cells. It also acts on other important immune procedures.
ITK Inhibitor
CPI-818 is an oral, small molecule drug and selectively inhibits ITK (interleukin-2-inducible T cell kinase). ITK is an enzyme expressed predominantly in T cells and that plays a role in T cell and natural killer (NK) cell lymphomas and leukemias, as well as in normal immune function.
Our CPI-818 has dual properties: to block malignant T cell growth, and to modulate immune responses. We believe inhibiting ITK may be of therapeutic benefit for patients with T-cell lymphomas, certain B cell lymphomas and those with solid tumors because of its potential immune-enhancing properties.
ITK Inhibitor
CPI-818 is an oral, small molecule drug and selectively inhibits ITK (interleukin-2-inducible T cell kinase). ITK is an enzyme expressed predominantly in T cells and that plays a role in T cell and natural killer (NK) cell lymphomas and leukemias, as well as in normal immune function.
Our CPI-818 has dual properties: to block malignant T cell growth, and to modulate immune responses. We believe inhibiting ITK may be of therapeutic benefit for patients with T-cell lymphomas, certain B cell lymphomas and those with solid tumors because of its potential immune-enhancing properties.
